Zobrazeno 1 - 10
of 186
pro vyhledávání: '"S Walti"'
Autor:
Maxime Hentzien, Fabrice Bonnet, Enos Bernasconi, Emmanuel Biver, Dominique L. Braun, Aline Munting, Karoline Leuzinger, Olivier Leleux, Stefano Musardo, Virginie Prendki, Patrick Schmid, Cornelia Staehelin, Marcel Stoeckle, Carla S. Walti, Linda Wittkop, Victor Appay, Arnaud M. Didierlaurent, Alexandra Calmy
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background The burden of herpes zoster (shingles) virus and associated complications, such as post-herpetic neuralgia, is higher in older adults and has a significant impact on quality of life. The incidence of herpes zoster and post-herpeti
Externí odkaz:
https://doaj.org/article/3f8091d417ad43dbb2cb4768c4041a15
Autor:
Helen Y Chu, Caitlin R Wolf, Rebecca A Gardner, Cameron J Turtle, Joshua A Hill, Carla S Walti, Andrea N Loes, Kiel Shuey, Elizabeth M Krantz, Jim Boonyaratanakornkit, Jacob Keane-Candib, Tillie Loeffelholz, Justin J Taylor, Damian J Green, Andrew J Cowan, David G Maloney, Steven A Pergam, Jesse D Bloom
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/287ae1b301ef47aab23e2cd038c0f88b
Autor:
Carla S. Walti, Elizabeth M. Krantz, Joyce Maalouf, Jim Boonyaratanakornkit, Jacob Keane-Candib, Laurel Joncas-Schronce, Terry Stevens-Ayers, Sayan Dasgupta, Justin J. Taylor, Alexandre V. Hirayama, Merav Bar, Rebecca A. Gardner, Andrew J. Cowan, Damian J. Green, Michael J. Boeckh, David G. Maloney, Cameron J. Turtle, Joshua A. Hill
Publikováno v:
JCI Insight, Vol 6, Iss 11 (2021)
BACKGROUND Little is known about pathogen-specific humoral immunity after chimeric antigen receptor–modified T (CAR-T) cell therapy for B cell malignancies.METHODS We conducted a prospective cross-sectional study of CD19-targeted or B cell maturati
Externí odkaz:
https://doaj.org/article/e8eb2b57fba84a3cb68dc70fadfe02d3
Autor:
Carla S. Walti, Anna B. Halpern, Hu Xie, Erika S. Kiem, E. Lisa Chung, Kelda G. Schonhoff, Emily M. Huebner, Colleen Delaney, Catherine Liu, Steven A. Pergam, Guang-Shing Cheng, Louise E. Kimball, Wendy M. Leisenring, Michael Boeckh, Roland B. Walter, Joshua A. Hill
Publikováno v:
Leukemia. 37:298-307
Publikováno v:
Current Opinion in Infectious Diseases. 35:302-311
Double-stranded DNA (dsDNA) viruses remain important causes of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). As treatment options are limited, adoptive therapy with virus-specific T cells (VST) is promising in res
Publikováno v:
Expert Review of Hematology. 15:305-320
The unprecedented success of chimeric antigen receptor (CAR)-T-cell therapy in the management of B-cell malignancies comes with a price of specific side effects. Healthy B-cell depletion is an anticipated 'on-target' 'off-tumor' side effect and can c
Autor:
Julian Lindsay, Carla S. Walti, Anna B Halpern, Hu Xie, E Lisa Chung, Kelda G Schonhoff, Emily M Huebner, Guang-Shing Cheng, Louise Kimball, Wendy M Leisenring, Matthew Greenwood, Sharon C-A Chen, David CM Kong, Monica A. Slavin, Michael Boeckh, David Fredricks, Catherine Liu, Steven A. Pergam, Roland B Walter, Joshua A. Hill
Publikováno v:
Blood Advances.
CLAG-M (cladribine, high-dose cytarabine [HiDAC], G-CSF, mitoxantrone)/CLAG are contemporary intensive chemotherapy regimens associated with higher and deeper complete remission rates than 7+3 (cytarabine, anthracycline)/HiDAC, but with greater myelo
Autor:
Alexandre V. Hirayama, Damian J. Green, Terry Stevens-Ayers, Joshua A. Hill, Andrew J. Cowan, Justin J. Taylor, Joyce Maalouf, Laurel Joncas-Schronce, Carla S Walti, Jacob Keane-Candib, Elizabeth M Krantz, Jim Boonyaratanakornkit, Michael Boeckh, Rebecca Gardner, Merav Bar, Cameron J. Turtle, David G. Maloney, Sayan Dasgupta
Publikováno v:
JCI Insight
BACKGROUND Little is known about pathogen-specific humoral immunity after chimeric antigen receptor–modified T (CAR-T) cell therapy for B cell malignancies. METHODS We conducted a prospective cross-sectional study of CD19-targeted or B cell maturat
Autor:
Joshua A. Hill, Carla S Walti, Jim Boonyaratanakornkit, Jesse D. Bloom, David G. Maloney, Tillie Loeffelholz, Andrea N. Loes, Kiel Shuey, Elizabeth M Krantz, Rebecca Gardner, Dylan Green, Andrew J. Cowan, Helen Y. Chu, Steven A. Pergam, Cameron J. Turtle, Caitlin R Wolf, Justin J. Taylor, Jacob Keane-Candib
Recipients of chimeric antigen receptor-modified T (CAR-T) cell therapies for B-cell malignancies are immunocompromised and at risk for serious infections. Vaccine immunogenicity is unknown in this population. We conducted a prospective observational
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d784170e60b0bcc9ed1e45b2aea176c6
https://doi.org/10.1101/2021.05.10.21256634
https://doi.org/10.1101/2021.05.10.21256634
Publikováno v:
Ann Am Thorac Soc